Integra LifeSciences Launches Portfolio of Advanced Orthobiologics for Spine Surgery

Share this story with your network

PLAINSBORO, N.J., March 9, 2010 (GLOBE NEWSWIRE) — Integra Lifesciences Holdings Corporation (Nasdaq:IART) announced today that it has created a portfolio of advanced bone grafting products, which will be sold in conjunction with its Integra Spine implants, providing spine surgeons a comprehensive set of solutions for spine fusion.

Bone graft substitutes provide a foundation or scaffold for the patient’s body to grow new bone, and can stimulate new bone production and bone fusion. Bone graft substitutes may also reduce or replace the need to harvest the patient’s own bone, thus sparing additional surgery and potential co-morbidity

The portfolio includes three bone grafting technology platforms:

OsteoSparx™ Demineralized Bone Matrix: Integra’s first generation Demineralized Bone Matrix (DBM) technology, incorporating a standard DBM and Integra’s unique poloxamer Reverse Phase Medium. The poloxamer is flowable at room temperature and becomes viscous at body temperature.

OsteoSurge™ Demineralized Bone Matrix: Integra’s Advanced DBM, which is powered by the Accell® technology and composed of an optimized blend of particulate DBM, Integra’s proprietary Accell® Bone Matrix (ABM), and the poloxamer Reverse Phase Medium.  ABM is an open structured and more dispersed form of DBM, allowing greater access to bone proteins that creates a favorable environment for bone formation without the need for partial breakdown of the implanted material.

OsteoStrux™ Osteoconductive Scaffold: Integra’s collagen ceramic matrix, incorporating Integra’s proprietary Type I collagen technology. Integra’s  Type I collagen is the basic ingredient in many of Integra’s advanced regenerative technologies such as DuraGen® Plus Dural Regeneration Matrix, NeuraGen® Nerve Guide, and INTEGRA® Dermal Regeneration Template, and has been implanted in over 12 million patients worldwide.   This collagen ceramic matrix provides an ideal scaffold for bone regeneration.

“Integra is committed to growing our spine business, and capitalizing on the synergies between our spine and orthobiologic franchises is key to this growth,” said Brian Larkin, Integra’s Group President. “By introducing one of the broadest bone regenerative product portfolios available in the orthopedic market through our spine distribution channel, we are confirming our commitment to invest in and strengthen our spine business. Additionally, this strategy allows us to maintain our commitment to meeting the needs of our general orthopedic distributors.”

The U.S. market size for bone graft substitutes in orthopedic spinal procedures is estimated at $1.5 billion. In 2009, an estimated 1,000,000 orthopedic procedures were performed in the United States, including over 500,000 spinal fusions. Additional applications are found in orthopedic trauma and reconstructive procedures.

The OsteoSparx™, OsteoSurge™ and OsteoStrux™ bone graft substitute products are distributed through the Integra Spine independent distributor network. Integra Spine is a leading provider of fusion implants and orthobiologics used in spinal surgery. Visit www.integraspine.com for more information.

Integra LifeSciences Holdings Corporation, a world leader in regenerative medicine, is a global medical device company dedicated to improving the quality of life for millions of patients each year. The company’s products are used primarily in orthopedics, neurosurgery and general surgery. Headquartered in Plainsboro, New Jersey, Integra has research and manufacturing facilities throughout the world. For more information, visit www.integra-ls.com.

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements concerning the future use of Integra products. Such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from predicted or expected results. Among other things, the willingness of physicians to use these products may affect the prospects for their use in clinical procedures. In addition, economic, competitive, governmental, technological and other factors identified under the heading “Risk Factors” included in Item IA of Integra’s Annual Report on Form 10-K for the year ended December 31, 2009 and information contained in subsequent filings with the Securities and Exchange Commission could affect actual results.

IART-P

CONTACT:  Integra LifeSciences Holdings Corporation
          Gianna Sabella, Director of Corporate Communications
          (609) 936-2389
          gsabella@integra-LS.com

Leave a Comment

Your email address will not be published. Required fields are marked *

*